Ambys Medicines
Ambys Medicines develops cell therapies to treat severe liver diseases, pioneering the novel application of cell therapy approaches to restore and reverse liver disease progression. The company's lead candidate, AMI-9, is designed to address life-threatening liver conditions by leveraging cellular regenerative medicine approaches that go beyond traditional pharmaceutical treatments. Ambys focuses on developing…
Funding snapshot
About
Ambys Medicines develops cell therapies to treat severe liver diseases, pioneering the novel application of cell therapy approaches to restore and reverse liver disease progression. The company's lead candidate, AMI-9, is designed to address life-threatening liver conditions by leveraging cellular regenerative medicine approaches that go beyond traditional pharmaceutical treatments. Ambys focuses on developing therapies that can halt or reverse the progression of severe liver diseases where current treatment options are limited, potentially reducing the need for liver transplantation. The company combines expertise in cell biology, hepatology, and translational medicine to advance its therapeutic pipeline. Founded in 2018 and headquartered in Redwood City, California, Ambys Medicines has raised approximately $107 million in Series A funding from investors including Third Rock Ventures, Takeda, Schroders, Laurion Capital, and Alexandria.
Business model
Metabolic Diseases > Drugs > Hepatic disorders,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Team background
College Wise > Massachusetts Institute of Technology, Harvard University
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.